Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Sipuleucel-T for the treatment of prostate cancer.

Harzstark AL, Small EJ.

Drugs Today (Barc). 2008 Apr;44(4):271-8. Review.

PMID:
18536785
2.

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).

Harzstark AL, Small EJ.

Expert Opin Biol Ther. 2007 Aug;7(8):1275-80. Review.

PMID:
17696825
3.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
4.

Sipuleucel-T (APC8015) for prostate cancer.

So-Rosillo R, Small EJ.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1163-7. Review.

PMID:
17020451
5.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

6.

Dendritic cell-based immunotherapy for prostate cancer.

Jähnisch H, Füssel S, Kiessling A, Wehner R, Zastrow S, Bachmann M, Rieber EP, Wirth MP, Schmitz M.

Clin Dev Immunol. 2010;2010:517493. doi: 10.1155/2010/517493. Epub 2010 Nov 4. Review.

7.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

8.

Cancer immunotherapy: sipuleucel-T and beyond.

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.

Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813. Review.

9.

Sipuleucel-T: Prototype for development of anti-tumor vaccines.

Carballido E, Fishman M.

Curr Oncol Rep. 2011 Apr;13(2):112-9. doi: 10.1007/s11912-011-0152-5. Review.

PMID:
21243538
10.

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.

Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review.

PMID:
22036643
11.

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.

Thara E, Dorff TB, Pinski JK, Quinn DI.

Maturitas. 2011 Aug;69(4):296-303. doi: 10.1016/j.maturitas.2011.04.012. Epub 2011 May 31. Review.

PMID:
21621934
12.

Sipuleucel-T: in metastatic castration-resistant prostate cancer.

Plosker GL.

Drugs. 2011 Jan 1;71(1):101-8. doi: 10.2165/11206840-000000000-00000. Review.

PMID:
21175243
13.

The evolving role of immunotherapy in prostate cancer.

Gerritsen WR.

Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259. Review.

PMID:
22918924
14.

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Patel PH, Kockler DR.

Ann Pharmacother. 2008 Jan;42(1):91-8. Epub 2007 Dec 19. Review.

PMID:
18094343
15.

Advances in prostate cancer immunotherapies.

Basler M, Groettrup M.

Drugs Aging. 2007;24(3):197-221. Review.

PMID:
17362049
16.

Prostate cancer vaccines: current status and future potential.

Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D.

BioDrugs. 2008;22(2):71-84. Review.

PMID:
18345705
17.

Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.

Gardner TA, Elzey BD, Hahn NM.

Hum Vaccin Immunother. 2012 Apr;8(4):534-9. doi: 10.4161/hv.19795. Review.

PMID:
22832254
18.

Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.

Wei XX, Fong L, Small EJ.

Expert Rev Vaccines. 2015;14(12):1529-41. doi: 10.1586/14760584.2015.1099437. Epub 2015 Oct 21. Review.

PMID:
26488270
19.

An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.

Wesley JD, Whitmore J, Trager J, Sheikh N.

Hum Vaccin Immunother. 2012 Apr;8(4):520-7. doi: 10.4161/hv.18769. Epub 2012 Feb 28. Review.

PMID:
22370520
20.

Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?

Lü C, Williams AK, Chalasani V, Martínez CH, Chin J.

Expert Opin Biol Ther. 2011 Jan;11(1):99-108. doi: 10.1517/14712598.2011.538677. Epub 2010 Nov 17. Review.

PMID:
21080858

Supplemental Content

Support Center